perflutren 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
perfluorinated compounds used as blood substitutes and/or diagnostic agents 2104 76-19-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • luminity
  • perflutren
  • octafluoropropane
  • perfluoropropane
Perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood. These physical acoustic properties of activated perflutren provide contrast enhancement of the left ventricular chamber and aid delineation of the left ventricular endocardial border during echocardiography.
  • Molecular weight: 188.02
  • Formula: C3F8
  • CLOGP: 2.85
  • LIPINSKI: 0
  • HAC: 0
  • HDO: 0
  • TPSA:
  • ALOGS: -3.11
  • ROTB: 2
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 1.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 590.71 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.02 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 31, 2001 FDA LANTHEUS MEDCL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Back pain 771.57 48.30 282 1514 263863 63223363
Flushing 133.49 48.30 57 1739 75030 63412196
Muscle spasms 120.71 48.30 67 1729 156083 63331143
Neck pain 92.21 48.30 43 1753 69275 63417951
Dyspnoea 89.95 48.30 101 1695 661212 62826014
Chest pain 66.06 48.30 52 1744 215907 63271319
Contrast media reaction 59.26 48.30 12 1784 1113 63486113
Pain in extremity 52.26 48.30 55 1741 331431 63155795
Urticaria 50.78 48.30 40 1756 165762 63321464

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Back pain 791.53 58.87 266 1327 121523 34833815
Muscle spasms 196.98 58.87 86 1507 74915 34880423
Flushing 107.38 58.87 44 1549 32376 34922962
Urticaria 102.75 58.87 52 1541 62325 34893013
Neck pain 79.10 58.87 33 1560 25316 34930022
Anaphylactic reaction 65.22 58.87 31 1562 32270 34923068
Pain in extremity 62.22 58.87 49 1544 126464 34828874

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Back pain 1378.02 53.32 494 2747 303686 79437461
Muscle spasms 311.68 53.32 148 3093 174582 79566565
Flushing 224.46 53.32 96 3145 88172 79652975
Neck pain 146.48 53.32 68 3173 75349 79665798
Urticaria 112.68 53.32 78 3163 185123 79556024
Dyspnoea 100.01 53.32 146 3095 856879 78884268
Pain in extremity 95.47 53.32 94 3147 364444 79376703
Contrast media reaction 95.07 53.32 21 3220 2049 79739098
Anaphylactic reaction 80.09 53.32 47 3194 83696 79657451
Chest pain 77.91 53.32 75 3166 282229 79458918
Flank pain 72.24 53.32 28 3213 19816 79721331

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08DA01 VARIOUS
CONTRAST MEDIA
ULTRASOUND CONTRAST MEDIA
Ultrasound contrast media
ATC V08DA04 VARIOUS
CONTRAST MEDIA
ULTRASOUND CONTRAST MEDIA
Ultrasound contrast media
FDA MoA N0000010259 Ultrasound Contrast Activity
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA EPC N0000175864 Contrast Agent for Ultrasound Imaging

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Echocardiography indication 40701008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
6.52MG/ML DEFINITY LANTHEUS MEDCL N021064 July 31, 2001 RX INJECTABLE INTRAVENOUS 10583207 Dec. 28, 2035 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY RT LANTHEUS MEDCL N021064 Nov. 17, 2020 RX INJECTABLE INTRAVENOUS 10583207 Dec. 28, 2035 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY RT LANTHEUS MEDCL N021064 Nov. 17, 2020 RX INJECTABLE INTRAVENOUS 11395856 Dec. 28, 2035 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY LANTHEUS MEDCL N021064 July 31, 2001 RX INJECTABLE INTRAVENOUS 10583208 March 16, 2037 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY RT LANTHEUS MEDCL N021064 Nov. 17, 2020 RX INJECTABLE INTRAVENOUS 10583208 March 16, 2037 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY LANTHEUS MEDCL N021064 July 31, 2001 RX INJECTABLE INTRAVENOUS 11266750 March 16, 2037 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY RT LANTHEUS MEDCL N021064 Nov. 17, 2020 RX INJECTABLE INTRAVENOUS 11266750 March 16, 2037 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY LANTHEUS MEDCL N021064 July 31, 2001 RX INJECTABLE INTRAVENOUS 11529431 March 16, 2037 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY RT LANTHEUS MEDCL N021064 Nov. 17, 2020 RX INJECTABLE INTRAVENOUS 11529431 March 16, 2037 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY LANTHEUS MEDCL N021064 July 31, 2001 RX INJECTABLE INTRAVENOUS 9789210 March 16, 2037 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY RT LANTHEUS MEDCL N021064 Nov. 17, 2020 RX INJECTABLE INTRAVENOUS 9789210 March 16, 2037 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY LANTHEUS MEDCL N021064 July 31, 2001 RX INJECTABLE INTRAVENOUS 10588988 May 4, 2037 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
6.52MG/ML DEFINITY RT LANTHEUS MEDCL N021064 Nov. 17, 2020 RX INJECTABLE INTRAVENOUS 10588988 May 4, 2037 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4024282 VUID
N0000148772 NUI
D01738 KEGG_DRUG
4021302 VANDF
4021353 VANDF
4024282 VANDF
C0937858 UMLSCUI
CHEBI:31980 CHEBI
CHEMBL1663 ChEMBL_ID
DB00556 DRUGBANK_ID
6432 PUBCHEM_CID
7932 INN_ID
C042852 MESH_SUPPLEMENTAL_RECORD_UI
CK0N3WH0SR UNII
283753 RXNORM
16500 MMSL
d04796 MMSL
009302 NDDF
409291008 SNOMEDCT_US
409292001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Optison Perflutren Protein-Type A Microspheres HUMAN PRESCRIPTION DRUG LABEL 2 0407-2707 INJECTION, SOLUTION 0.22 mg INTRAVENOUS NDA 28 sections
Optison Perflutren Protein-Type A Microspheres HUMAN PRESCRIPTION DRUG LABEL 2 0407-2707 INJECTION, SOLUTION 0.22 mg INTRAVENOUS NDA 28 sections
Definity HUMAN PRESCRIPTION DRUG LABEL 1 11994-011 INJECTION, SUSPENSION 6.52 mg INTRAVENOUS NDA 25 sections
Definity HUMAN PRESCRIPTION DRUG LABEL 1 11994-011 INJECTION, SUSPENSION 6.52 mg INTRAVENOUS NDA 25 sections
Definity HUMAN PRESCRIPTION DRUG LABEL 1 11994-011 INJECTION, SUSPENSION 6.52 mg INTRAVENOUS NDA 25 sections
DEFINITY RT HUMAN PRESCRIPTION DRUG LABEL 1 11994-017 INJECTION, SUSPENSION 6.52 mg INTRAVENOUS NDA 27 sections
DEFINITY RT HUMAN PRESCRIPTION DRUG LABEL 1 11994-017 INJECTION, SUSPENSION 6.52 mg INTRAVENOUS NDA 27 sections